- Ondaro, Jon
- Zúñiga Elizari, Jose Luis
- Zufiría García, Mónica
- Garciandia-Arcelus, Maddi
- Sánchez Molleda, Ángela
- Zulaica Ijurco, Miren
- Lafarga, Miguel
- Riancho, Javier
- López de Munain, Adolfo
- Moreno, Fermin
- Gil Bea, Francisco Javier
- Gerenu, Gorka
Frontotemporal dementia (FTD) is a neurodegenerative disorder predominantly affecting individuals under 65 years of age, characterized by significant behavioral and language disabilities. Despite extensive research efforts, effective treatments for FTD remain elusive. Familial cases of FTD have been linked to genetic mutations in several key genes, among these, mutations in granulin (GRN) account for 5–20% of cases, leading to haploinsufficiency of progranulin (PGRN), a multifunctional glycoprotein. This study investigates the cellular pathology associated with GRN insufficiency by using fibroblasts derived from FTD patients carrying the c.709-1G>A GRN mutation (FTD-GRN). These fibroblasts exhibited pathological hallmarks of FTD, including lysosomes, autophagosomes, and lipofuscin accumulation, mirroring observations in affected patient tissues. Notably, we report mitochondrial abnormalities, characterized by mitochondrial swelling which is associated with decreased mitochondrial respiration, and lipid droplet accumulation, reflecting altered lipid metabolism. Experimental supplementation with recombinant human progranulin (rhPGRN) was associated with recovery of lysosomal acidification and attenuation of mitochondrial and lipid abnormalities in vitro. This study reveals that GRN haploinsufficiency induces mitochondrial and lipid dysfunctions, suggesting that these pathways may contribute to FTD-GRN pathogenesis and could be of interest for therapeutic development., This research was funded by Grant PID2023-153029OA-I00 funded by MICIU/AEI/10.13039/501100011033 and, as appropriate, by 'ERDF A way of making Europe', by 'ERDF/EU', by the 'European Union' or by the 'European Union NextGenerationEU/PRTR'. The Instituto de Salud Carlos III (ISCIII) and co-funded by the European Union through the European Regional Development Fund (ERDF) (grant numbers P18/01066, PI19/01637, PI21/00153, PI24/01025); by CIBERNED-Centro de Investigación Biomédica en Red de Enfermedades Neurodegenerativas (grant number CB06/05/1126, Group 609); by the Diputación Foral de Gipuzkoa (project 2021-CIEN-000020-01); by EiTB Maratoia (BIO17/ND/023/BD); by Fundació La Marató (grant number 202006-32); and by the IKUR strategy of the Basque Government (NEURODEGENPROT project), as well as the Basque Government Department of Health (Eusko Jaurlaritzako Osasun Saila; grant numbers 2017222027, 2018111042, 2019222020, and 2021333050). J.O., J.L., M.Z., and M.G. received predoctoral support from the Department of Education of the Basque Government through grants PRE2018_1_0095, PRE2022_1_0315, PRE2015_1_0023, and PRE2020_1_0122, respectively. F.G. was supported by the Roche 'Stop Fuga de Cerebros' program (BIO19/ROCHE/017/BD). G.G. was funded by the Juan de la Cierva-Incorporación fellowship from the Spanish Ministry of Science and Innovation (IJC2019-039965-I). F.G., and G.G. received additional support from the IKERBASQUE Research Foundation. The APC was funded by the same funding sources, in accordance with the authors' affiliation with the University of the Basque Country (UPV/EHU).